Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RENOVE trial: reduced-dose vs full-dose DOAC after unprovoked VTE
2017-002433-31Phase 3Completed
- Sponsor
- Centre Hospitalier Universitaire de Brest
- Start
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of apixaban and rivaroxaban in venous thromboembolism (VTE), pulmonary embolism (PE) and deep vein thrombosis (DVT) (2 arms), sponsored by Centre Hospitalier Universitaire de Brest. Started Jun 2017; status: completed.
02
Drugs
apixabanrivaroxaban
03
Conditions
venous thromboembolism (VTE)pulmonary embolism (PE)deep vein thrombosis (DVT)
Beyond the preview
Go deeper on 2017-002433-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002433-31.